Q2 and First Half Year Results ended 30 June 2026

AI SummaryClose X

CelLBxHealth plc reported a significant increase in Q2 revenue, which doubled compared to Q1, reaching £0.4 million, contributing to a first-half revenue of £0.6 million. The company also achieved a gross profit of £0.4 million with a 61% gross margin, and substantially reduced its operating loss to £2.7 million for the first half of 2026, down from £9.7 million in the prior year period. This reduction in operating loss is attributed to a restructuring program that lowered the annualised operating cash cost base to approximately £6.3 million, effectively cutting cash burn despite £1.5 million in restructuring payments. The company ended the period with £2.9 million in cash and cash equivalents, and anticipates an average monthly cash burn of £0.3 million to £0.4 million moving forward, providing a cash runway into Q2 2027.

Disclaimer*

UK 100

Latest directors dealings